Cambridge Investment Research Advisors
NKTR icon

Cambridge Investment Research Advisors’s Nektar Therapeutics NKTR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Buy
56,186
+131
+0.2% +$9.59K 0.01% 1182
2026
Q1 		$4.03M Buy
56,055
+2,342
+4% +$133K 0.01% 1094
2025
Q4 		$2.27M Buy
53,713
+7,077
+15% +$396K 0.01% 1421
2025
Q3 		$2.65M Buy
46,636
+34,554
+286% +$1.14M 0.01% 1294
2025
Q2 		$312K Buy
12,082
+3,017
+33% +$33.9K ﹤0.01% 2945
2025
Q1 		$92K Buy
9,065
+615
+7% +$8.04K ﹤0.01% 3358
2024
Q4 		$118K Sell
8,450
-362
-4% -$6.38K ﹤0.01% 3307
2024
Q3 		$172K Buy
8,812
+620
+8% +$11.8K ﹤0.01% 3191
2024
Q2 		$152K Sell
8,192
-209
-2% -$4.41K ﹤0.01% 3102
2024
Q1 		$118K Sell
8,401
-260
-3% -$2.72K ﹤0.01% 3133
2023
Q4 		$73K Sell
8,661
-318
-4% -$2.41K ﹤0.01% 3070
2023
Q3 		$80K Sell
8,979
-151
-2% -$1.45K ﹤0.01% 2992
2023
Q2 		$79K Sell
9,130
-14
-0.2% -$149 ﹤0.01% 3039
2023
Q1 		$96K Buy
9,144
+329
+4% +$9.95K ﹤0.01% 2970
2022
Q4 		$299K Buy
+8,815
New +$427K ﹤0.01% 2432
2021
Q3 		– Sell
-686
Closed -$177K – 3160
2021
Q2 		$177K Sell
686
-2
-0.3% -$554 ﹤0.01% 2869
2021
Q1 		$206K Sell
688
-29
-4% -$9.03K ﹤0.01% 2598
2020
Q4 		$183K Sell
717
-74
-9% -$19.1K ﹤0.01% 2500
2020
Q3 		$197K Buy
791
+1
+0.1% +$315 ﹤0.01% 2241
2020
Q2 		$275K Sell
790
-60
-7% -$18.7K ﹤0.01% 1951
2020
Q1 		$227K Sell
850
-37
-4% -$11.4K ﹤0.01% 1850
2019
Q4 		$287K Sell
887
-89
-9% -$25.8K ﹤0.01% 1937
2019
Q3 		$267K Buy
976
+8
+0.8% +$2.93K ﹤0.01% 1910
2019
Q2 		$517K Buy
968
+81
+9% +$40.6K ﹤0.01% 1401
2019
Q1 		$447K Buy
887
+184
+26% +$109K ﹤0.01% 1565
2018
Q4 		$347K Sell
703
-89
-11% -$53.7K ﹤0.01% 1563
2018
Q3 		$724K Buy
792
+473
+148% +$404K 0.01% 1225
2018
Q2 		$234K Buy
319
+68
+27% +$78.4K ﹤0.01% 1900
2018
Q1 		$400K Buy
251
+7
+3% +$9.02K ﹤0.01% 1468
2017
Q4 		$219K Buy
+244
New +$144K ﹤0.01% 1866

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's NKTR Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Nektar Therapeutics (NKTR) stake by 0.23% in Q2 2026, buying an estimated $9.59K and bringing the position to 56,186 shares worth $3.92M. The position accounts for 0.01% of the portfolio, ranked #1182.

Cambridge Investment Research Advisors first reported a position in NKTR in Q4 2017 and has held it in 30 quarters since. The position peaked at $4.03M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Cambridge Investment Research Advisors held 56,186 shares of Nektar Therapeutics worth $3.92M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 131 Nektar Therapeutics shares in Q2 2026, an estimated $9.59K.
  • Nektar Therapeutics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1182 holding.
  • Cambridge Investment Research Advisors first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 30 quarters since.
  • Cambridge Investment Research Advisors's Nektar Therapeutics position peaked at $4.03M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.